CN111172189B - Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome - Google Patents
Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome Download PDFInfo
- Publication number
- CN111172189B CN111172189B CN201811346983.9A CN201811346983A CN111172189B CN 111172189 B CN111172189 B CN 111172189B CN 201811346983 A CN201811346983 A CN 201811346983A CN 111172189 B CN111172189 B CN 111172189B
- Authority
- CN
- China
- Prior art keywords
- medaka
- gsdf
- male
- female
- egfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000276569 Oryzias latipes Species 0.000 title claims abstract description 51
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 14
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 8
- 230000002611 ovarian Effects 0.000 title abstract description 12
- 230000009261 transgenic effect Effects 0.000 claims abstract description 34
- 241000251468 Actinopterygii Species 0.000 claims abstract description 31
- 238000009396 hybridization Methods 0.000 claims abstract description 12
- 230000002068 genetic effect Effects 0.000 claims abstract description 10
- 238000009395 breeding Methods 0.000 claims abstract description 8
- 230000001488 breeding effect Effects 0.000 claims abstract description 8
- 235000013601 eggs Nutrition 0.000 claims description 19
- 239000013613 expression plasmid Substances 0.000 claims description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 abstract description 15
- 210000001672 ovary Anatomy 0.000 abstract description 14
- 230000010196 hermaphroditism Effects 0.000 abstract description 12
- 238000010171 animal model Methods 0.000 abstract description 11
- 210000000695 crystalline len Anatomy 0.000 abstract description 11
- 210000004602 germ cell Anatomy 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 108700019146 Transgenes Proteins 0.000 abstract description 7
- 230000009456 molecular mechanism Effects 0.000 abstract description 5
- 230000004186 co-expression Effects 0.000 abstract description 3
- 230000005014 ectopic expression Effects 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 19
- 210000002149 gonad Anatomy 0.000 description 13
- 210000001550 testis Anatomy 0.000 description 13
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000002710 gonadal effect Effects 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000020509 sex determination Effects 0.000 description 7
- 101100058760 Danio rerio cyp19a1a gene Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000035558 fertility Effects 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000021595 spermatogenesis Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 210000002503 granulosa cell Anatomy 0.000 description 4
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 101150105763 FSHR gene Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101100277928 Xenopus laevis dmrt1-a gene Proteins 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 101150078435 dmrt1 gene Proteins 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000004377 supraoptic nucleus Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 2
- 102000014824 Crystallins Human genes 0.000 description 2
- 108010064003 Crystallins Proteins 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100322565 Mus musculus Adam3 gene Proteins 0.000 description 2
- 101710162501 Ovarian aromatase Proteins 0.000 description 2
- 210000002593 Y chromosome Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000000799 primary oocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000000920 spermatogeneic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 101710197961 Brain aromatase Proteins 0.000 description 1
- 108010092265 CCWGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 101150051357 CYP17A1 gene Proteins 0.000 description 1
- 101150056519 CYP19A1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 108010021310 endodeoxyribonuclease NcoI Proteins 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940042345 estradiol / testosterone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000013069 gamma-Crystallins Human genes 0.000 description 1
- 108010079934 gamma-Crystallins Proteins 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000023508 male gonad development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000801 secondary oocyte Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for establishing a Sissy medaka model for simulating human spermatic ovarian syndrome, which comprises the following steps: a) Breeding to obtain the gsdf KO medaka of the homozygous female fish with the gsdf knocked out by using the gsdf specific primer; b) Utilizing crystalline lens co-expression gsdf2AEGFP plasmid to establish gsdf ectopic expression transgene XX male species fish Tg, cryGsdf2A-EGFP; c) Genetic hybridization and breeding: the method comprises the steps of obtaining a gsdf heterozygous XXTg male medaka through the female hybridization of a cryGsf 2A-EGFP transgenic XX male fish and a gsdfKO, and finally obtaining the hermaphrodite Sissy medaka through the hybridization of the gsdf heterozygous XXTg male medaka and the gsdfKO female medaka. The invention establishes an animal model of the spermatid ovary by utilizing gene editor for the first time, and provides a living animal model for researching a molecular mechanism of female and male differentiation of germ cells and a pathogenesis of spermatid ovary generation.
Description
Technical Field
The invention relates to establishment of a disease model experimental animal model, in particular to an establishment method of a Sissy medaka model for simulating human sperm ovarian syndrome.
Background
The gonadal development of human beings and animals is abnormal due to genetic or epigenetic factors, environmental society and other factors, so that fertility or reproduction rate is obviously lower than that of normal individuals, gonadal cells, gonadal structure and function abnormality, tumor generation and other pathological changes, and the reproductive health of human beings and animals is increasingly influenced and threatened in recent years. Common but unknown pathogenesis is that human sperm ovarian signs, gonadal dysplasia or testis cancer is due to the fact that the male sex of humans is determined by the SRY male determinants of the Y chromosome, but there are still many undiagnosed puzzles on how SRY coordinates other factors, together with the regulatory mechanism that regulates the final entry of germ cells into male differentiation and development.
The development of male sterility treating method and contraceptive medicine needs corresponding animal model to develop deeply.
Patent document CN103361336a, publication date 2013.10.23, discloses a male fertility disorder animal model of a non-human mammal, a preparation method and use of the animal model, and the functions of the Prss37 gene and protein are identified. The Prss37 gene of the animal model is inactivated, thereby affecting the appearance of ADAM3 in mature sperm produced by the model animal, indirectly affecting sperm-zona pellucida binding and sperm migration from uterus to oviduct, resulting in serious male fertility disorders. The model and Prss37 gene and proteins thereof can be used for screening ADAM3 maturation promoters and infertility treatment agents or contraceptives.
However, to date, animal models suitable for studying the developmental association of spermatogenesis are extremely rare.
The inventor of the application published a review paper in period 6 of journal heredity 2017 "overview of sex determination and sexual differentiation research progress of teleost fish with model organism", and disclosed that "the laboratory utilizes gene knockout or transgene over-expression gsdf, a growth transforming factor (TGF-beta), to realize regulation and control of male and female differentiation of medaka. We have also found that gsdf is not only a key factor in initiating the male differentiation pathway, but also acts on the early development of egg cells and regulates the expression of other related genes in the pituitary-gonadal axis reproductive endocrine feedback system ", but how to construct a refined ovarian hermaphrodite animal model remains a challenge.
Disclosure of Invention
The invention aims at overcoming the defects in the prior art, and provides a method for establishing a Sissay medaka model for simulating human spermatic ovarian syndrome.
It is a further object of the present invention to provide the use of the sisty medaka model.
In order to achieve the first object, the invention adopts the following technical scheme:
a method for building a Sissy medaka model for simulating human spermatic ovarian syndrome, comprising the following steps:
a) Breeding to obtain the gsdf knockout homozygote female fish gsdfKO female medaka by using the gsdf specific primer;
b) Separating XX transgenic male breeding fish with gsdf ectopic expression by using green fluorescence of crystalline lens: creating and linearizing a p817-gsdf2A-EGFP expression plasmid, and microinjecting fertilized eggs to obtain a stable inherited Tg: cryGsdf2A-EGFP transgenic line;
c) Genetic hybridization protocol: obtaining a gsdf heterozygous XXTg male medaka through the female hybridization of the cryGsf 2A-EGFP transgenic XX male fish and the gsdfKO, and finally obtaining the gsdfKO transgenic medaka, namely the Sissy medaka model through the hybridization of the gsdf heterozygous XXTg male medaka and the gsdfKO female medaka.
The sequence of the p817-gsdf2A-EGFP expression plasmid is shown in SEQ ID NO. 3.
The gsdfKO female medaka is obtained by knocking out endogenous gsdf with a zinc finger nuclease specific target.
The fertilized egg is a fertilized egg of 1 cell stage.
In order to achieve the second purpose, the invention adopts the following technical scheme:
the use of the Sissy medaka model selected from the group consisting of:
a) Research on molecular mechanisms related to sex determination and differentiation of human or animal;
b) Screening suspected intrinsic or extrinsic environmental factors affecting the control of developmental differentiation of human or animal germ cells.
The animals cover lower to higher vertebrates including fish, amphibians, reptiles, birds, and mammals including mice, dogs, rabbits, monkeys, and humans.
The invention has the advantages that:
according to the invention, an animal model of the hermaphrodite sperm ovary, namely a Sissy medaka model, is successfully established for the first time, in the model, gsdf is introduced into local cells of homozygotes with the gsdf removed from genome, so that uneven distribution of gsdf signal expression cells is caused, disorder of microenvironment of germ cells and surrounding somatic cells is influenced, and germ cells under the action of the somatic cells with positive gsdf expression are promoted to enter a spermatogenic pathway; germ cells under the action of gsdf expressing negative somatic cells enter the ovum production process, eventually leading to the formation of both sperm and immature ovum cells in the same gonad.
1. The invention lays a foundation for researching the molecular mechanism research of a signal regulation path in the sex conversion process of the natural hermaphrodite fish in female-male differentiation development of the germ cells of fish, expects to reveal how different fish sex determination mechanisms of hermaphrodite and/or hermaphrodite lead the germ cells to finally enter the mutual association of hermaphrodite differentiation to evolve a conserved molecular mechanism, establishes a model of how related genes and proteins interact to form molecular network regulation, and provides theoretical basis for sex control and genetic operation of the fish. The invention is also convenient for screening chemical or/and environmental endocrine disruptors affecting the differentiation of male and female gonads of fishes in river water bodies.
2. In vertebrate phylogenetic evolution, fish are in a critical position after the front-opening. Compared with higher vertebrates, the sex determination mechanism of fish has originality, diversity and variability, and has sex determination modes of all vertebrates, various sex types from hermaphrodite to hermaphrodite exist, sex reversal is a more common phenomenon in fish, and therefore, research on the sex determination mechanism of fish has very important theoretical value for the formation of the sex determination mechanism of the whole vertebrate group and the disclosure of evolutionary pathways. The Sissy refined ovarian hermaphroditic medaka provided by the invention provides a living platform and a test material for further screening related suspected internal or external environmental factors influencing and controlling development and differentiation of germ cells, analyzing pathogenic mechanisms of pathological changes such as fertility decline or abnormal proliferation, and the like, is beneficial to analyzing the pathogenic mechanisms and mechanisms of infertility caused by overall low fertility trend and increasing infertility of people and animals, and discussing solutions and countermeasures.
Drawings
Fig. 1: and (5) genotyping.
Fig. 2: establishment of expression vectors and transgenic medaka lines for p817-gsdf 2A-EGFP. Gsdf is overexpressed in the lens of transgenic medaka. Schematic representation of the expression vector of (a). EGFP is expressed in the embryonic lens from 4 days post fertilization to adulthood. Eighth day after fertilization, embryos were examined at low power (b) and high power (b'); f0 generation (c and d) 3 months old transgenic fish.
Fig. 3: expression of EGFP signal in HPG axis.
Fig. 4: co-expression of the gsdf and cyp19b genes in WT XY male and Tg: cryGsdf2A-EGFP XX male brains. ICH analysis was performed with anti-Cyp 19b and Gsdf antibodies for WTYX (b is a magnified image of b') and Tg: cryGsdf2A-EGFP XX. Endogenous Gsdf was found mainly in the supraoptic nucleus (SC) and a small number of Cyp19b positive neurohypophysis cells (arrows). In both the pituitary and hypothalamus of transgenic individuals, both cyp19b positive and negative cells were able to observe an anti-Gsdf response signal (arrow), demonstrating that Gsdf is expressed in these cells.
Fig. 5: two-step genetic scheme. Obtaining XX male from the Tg cryGsdf2A-EGFP transgenic line, and obtaining gsdf mutant XY female by gsdf knockout; the gsdf homozygote and heterozygote transgenic individual are hybridized to finally obtain Sissy (gsdf-/-Tg: cryGsdf2A-EGFP XY).
Fig. 6: gsdf-/-XY male and normal XY female.
Fig. 7: silsy hermaphrodite appearance.
Fig. 8: testis of transgenic XX male.
Fig. 9: sissy refined ovaries. The green fluorescence (EGFP) signal can be detected by the lens of the transgenic individual; ruler = 1mm.
Fig. 10: histological analysis of cryGsdf2A-EGFP XX testis and Sissy ovary. (a) Tg cryGsdf2A-EGFP XX spermatic. (a') is an enlarged image of (a). (b) Spermatogenesis and oogenesis coexist in one spermatic ovary. And (b') is (b) a magnified image. Sg I, spermatogonial cell type I; sg II, spermatogonial cell type II; sc, spermatocyte; st, sperm cells; sz, sperm; od, double-line oocyte; op, pachytic oocytes; GC, germ stem cells (arrow).
Fig. 11: the expression of gonadal androgens (estradiol E2, testosterone T) synthesizing key enzyme (17 alpha-hydroxylase cyp17-a1; ovarian aromatase cyp19 a) and the level of androgens in blood. (a) cyp19a and cyp17a1 are key enzymes for E2 and T production and conversion, and are highly expressed in the ovary or testis, respectively. (b) The E2/T ratio in the serum of the male is lower and the E2/T ratio in the serum of the female is higher. All data were taken from serum mixtures of n=6 to 10 independent individuals and the ±se (n=3) was determined in more than three experimental replicates. * p < 0.01.WT: wild-type normal gsdf +/+; hm: knockout homozygote gsdf-/-; sissy: gsdf-/-Tg.
Fig. 12: transgenic overexpression of Gsdf signals stimulated the expression of follicle stimulating hormone (Fsh) receptor and brain aromatase (cyp 19 b).
Detailed Description
The following detailed description of the invention provides specific embodiments with reference to the accompanying drawings.
Example 1
1 Sissy medaka model establishment
1.1 breeding to obtain the homozygous female parent fish with the gsdf knocked out by using the gsdf specific primer
The medaka is fed in a water circulation system at 26-28deg.C, and the light and dark circulation time is 14/10 hr, and the treatment is strictly performed according to the instruction of the experimental animal research Commission of Shanghai university. Endogenous gsdf was knocked out with zinc finger protein nucleases (zinc-finger nucleic acids) specific targets, see previous report [1]. Assessment of sex phenotype was confirmed by secondary sex characteristics (dorsal and gluteal fin shapes) and gonadal anatomy. The primers (PG 17.55'-CCGGGTGCCCAAGTGCTCCCGCTG (SEQ ID NO: 4); PG 17.6.5' -GATCGTCCCTCCACAGAGAAGAGA (SEQ ID NO: 5)) were able to specifically amplify dmy and autosomal dmrt1 of the medaka Y chromosome, for the identification of XX and XY genotypes [2]. gsdf genotyping was performed according to our previously published paper [1].
Results: PCR amplification of genomic DNA was performed using a pair of primers (PG 17.5-17.6) to give XX pattern containing only 1.1kb band from dmrt1 and XY pattern containing both bands of dmrt1 and dmy (0.9 kb). Identification of gsdf wild type, heterozygotes and homozygotes, increased by 4 nucleotide bases based on the knockout mutant, forms a heterozygous band with the wild type allele, and homozygote DNA, when wild type DNA was not added, did not produce a heterozygous band, but after wild type DNA was added, a heterozygous band appeared to distinguish the genotype of the wild type individual (FIG. 1).
1.2 sorting out XX transgenic Male species of Fish with ectopic expression of gsdf by Green fluorescence of lens
Because gonads, pituitary glands and eyeballs are developmentally originated from the same cell line [3], microinjection of the mouse lens protein (gamma-crystallin) promoter drives the expression vector of green fluorescent protein (EGFP), which can produce transgenic medaka [4] with the lens expressed as green fluorescent EGFP. To investigate how gsdf modulates the molecular mechanism of gonadal differentiation via the hypothalamic-pituitary-gonadal axis (HPG), we performed the following redesign with the existing p817-EGFP expression plasmid. EGFP in p817-EGFP ([ 4] Addgene) is replaced by Gsdf2A-EGFP fragment, and Gsdf2A-EGFP fusion protein is introduced by using a 2A peptide-mediated co-expression system, so that green fluorescence-expressed cells can simultaneously overexpress Gsdf. The expression vector is injected by micro, so that the transgenic line Tg cryGsdf2A-EGFP is established. The resulting transgenic individuals showed green fluorescence of the lens from embryonic to adulthood, with continuous expression of Gsdf and EGFP on the HPG axis (fig. 2). The specific construction method of the vector is as follows:
the vector skeleton is taken from Dr Kozmik, constructed and published on an Addgene webpage, and p 817-mgama Fcry-EGFP (4280bp,ID 23156,www.addgene.org), called p817-EGFP for short. We linearized the vector p817-EGFP with EcoRI and NcoI endonucleases using PCR and In-Fusion HD Cloning(Clontech), the Gsdf-2A fragment was inserted in front of EGFP to give p817-Gsdf2A-EGFP, the full length of which was 4971 bp. The sequence of the synthetic vector segment adhesion primer is as follows:
gsdfFw1:5’-cttcccatcgattcgatgtctttggcactc(SEQ ID NO:1)
2ARv2:5’-GCCCTTGCTCACCATGGGCCCAGGGTTTTC(SEQ ID NO:2)
the gsdf2A fragment was amplified by PCR and ligated to the p 817-mgama Fcry-EGFP vector, named p817-gsdf2A-EGFP, with the pattern shown in FIG. 2A and the complete sequence shown in SEQ ID NO: 3. Sequencing confirms that the constructed expression plasmid is accurate.
By Invitrogen TM Plasmid DNA was extracted and the p817-gsdf2A-EGFP expression plasmid was linearized with I-SceI DNA endonuclease (Takara Dailian, china). Microinjection into the 1-cell stage of fertilized eggs was performed at a concentration of 50 ng/. Mu.l of DNA. Foundar species fish capable of being integrated and reproductive transferred to the offspring genome are obtained, transgenic individuals with green fluorescence at the lens at the beginning of embryo Stage (Stage 33) are obtained through genetic hybridization and PCR reaction can also detect fragments with corresponding sizes, and the gsdf2A-EGFP is proved to be integrated into the genome of the individuals. The mouse monoclonal antibodies against Gsdf and GFP detected positive expression cells in both brain and gonads, suggesting that these cells expressed both transgenic Gsdf and EGFP proteins.
Results: from the 1256 fertilized eggs injected, 17 sexually mature medaka were obtained, the lenses of which exhibited GFP fluorescence signals from the beginning of the embryo period (Stage 33) (b and b' in FIG. 2), and these transgenic fluorescence signals were continuously expressed to adults (c and d in FIG. 2).
The overall viability and transgene efficiency of the injected embryos are summarized in table 1. After 5 of them were selected to be outcrossed with wild females and males, 3F 0 Foundator fish (1 male fish and 2 female fish) transmitted GFP signals to offspring, indicating that transgenic expression of pGsdf2A-EGFP did not affect gonadal development. We note that GFP signals appear to be less sexual in F0 fish than in females (c and d in FIG. 2). No phenomenon similar to this sex difference was reported in the previous p817-EGFP Cab and Heino lines [4]. Mouse γF-lens driving factors regulate expression of lens proteins by local cell lines other than the lens, including retina, brain and testis [3]; we also detected gsdf-GFP signal in the brain and gonads (ovaries or spermary) of transgenic individuals (fig. 3), whereas no fluorescent signal was detected in the wild-type female and male brains or gonads as controls (fig. 3).
TABLE 1 Total survival and transgenic efficiency of p817-gsdf2A-EGFP medaka
1) A linear or circular expression plasmid DNA (pmγcry-gsdf2AEGFPDNA,40 ng/. Mu.l) was microinjected.
2) The percent survival was determined using the number of fertilized eggs injected as the denominator.
3) And (3) performing outcrossing on fish with green fluorescence on eyeballs and normal wild medaka, and detecting fertility of the fish.
4) Can transmit green fluorescence transgene signals to offspring's breeding fish.
Three Tg's, cryGsdf2A-EGFP transgenic families can obtain 17.4-44.4% XX males with different proportions in four filial generations of wild type, which indicates that the overexpression of gsdf in brain or/and gonad can promote XX male differentiation. In the F1 generation, 7/32 (21.9%) and 12/28 (42.9%) XX males were from two independent transgenic lines (Table 2). These transgenic F1 males were further hybridized with WT females, yielding approximately 50% gfp-positive XX males. Not all XX Tg, cryGsdf2A-EGFP, becomes XX male, presumably the local gsdf expression does not exceed the threshold required for XX maleation, or gsdf must be expressed in specific cells during critical stages of sexual differentiation, and the male pathway is initiated to promote XX maleation. In the Tg cryGsdf2A-EGFP line, most of hypothalamus and ovaries were GFP positive and pituitary GFP negative were XX female, whereas over 78% of XX males were hypothalamus-pituitary-testis (HPT) GFP positive (c 1-c4 in FIG. 3), consistent with our guessed local specific cell expression gsdf, which resulted in XX maleation hypothesis. Endogenous gsdf was detected in WTXX and XX Tg: cryGsdf2A-EGFP male medaka in the suprachiasmatic nucleus (SC) as shown in fig. 4 a and b, weakly in a few cells coexpressed with cyp19b in the pituitary region (arrow in fig. 4), or only gsdf positive cells in XX Tg: cryGsdf2A-EGFP male medaka (arrow in fig. 4), but not in WT females (data not shown).
TABLE 2 XX Male development of transgenic medaka
ND means no further tracking.
1.3 genetic hybridization protocol
The Sissy medaka is derived from the HdrR strain. XYgsdf KO female medaka was first obtained by hybridization between gsdf heterozygotes. Stable inherited Tg cryGsdf2A-EGFP transgenic lines were obtained by microinjection of fertilized eggs. And then obtaining the gsdf heterozygous XXTg male medaka by hybridizing the XX male fish with the Tg cryGsdf2A-EGFP transgene with the gsdfKO female. And hybridizing with the female medaka of the gsdfKO to finally obtain the gsdfKO transgenic medaka, i.e. Sissy.
Results: we used a two-step genetic hybridization protocol to generate Tg: cryGsdf2A-EGFP gsdf from initial mating of a male fish of Tg: cryGsdf2A-EGFPXX with a homozygous XY female of gsdf and continuous breeding of XX Tg: cryGsdf2A-EGFP male +/- Male and XY gsdf -/- Female (fig. 5). A Tg of cryGsdf2A-EGFPgsdf is obtained -/- XY medaka and named Sissy. genotyping of gsdf and dmy is summarized in table 3. 11 Tg's from 61 offspring cryGsdf2A-EGFP XYgsdf -/- Male and 8 Tg cryGsdf2A-EGFPXXgsdf -/- Female, following mendelian genetic law 1:1 (heterozygote: homozygote=31:30) separation (table 3). These 11 Sissy groups all exhibited male secondary sex characteristics, with their hip fins in the shape of parallelograms (FIGS. 6-7), all possessing a large abdomen. Dissections showed large abdominal cavities because their gonads were 4-5 times larger than normal XY or XX male testis (fig. 8-9).
TABLE 3 Tggsdf +/- XY and gsdf -/- Offspring genotyping of XX (male)
Gonadogenesis and spermatogenesis of medaka 2Sissy and sperm development are combined in the sperm ovary (Tg: cryGsdf 2A-EGFPgsdf) -/- )
Histological: the gonads of Sissy medaka and normal control group were fixed with Bouin's fixative (Picric acid: formaldehyde: glacial acetic acid 15:5:1), frozen, paraffin or resin embedded, and subjected to conventional or ultrathin sections. The thickness of a conventional tissue section is 5 μm, and the thickness of an ultrathin section observed by a transmission electron microscope is 60nm. Hematoxylin Eosin (HE) staining routinely observes cell morphology. Polychromatic fluorescence immunohistochemical analysis, observation and imaging analysis were performed with confocal laser scanning microscopy (Leica DMi8 TCS SP8, germany).
Results: histological analysis showed that the distal peripheral layer of the testis was thicker than the normal testis (a and a' in fig. 10), and that the spermatogonia were significantly proliferated. Although germ cells at different stages of development are packed during the outside-in seminiferous process from distal peripheral spermatogenic cells to proximal end spermatogenesis (b and b 'in fig. 10), there are also a large number of primary oocytes interspersed between seminal vesicles (b' in fig. 10), exhibiting the seminal ovarian phenomenon of concurrent egg production and spermatogenesis in the same gonad. In all 11 Sissy individuals we dissect, refined ovarian signs were present. Only primary oocytes that did not enter vitelline formation were not seen for secondary oocytes that entered vitelline formation, indicating that vitelline formation and/or vitelline absorption was regulated by Gsdf signals. We evaluated fertilization rates and embryo viability for Sissy sperm and the results are summarized in Table 4. In comparison with normal XY male testis, hermaphrodite Sissy was identical to normal female (wild type gsdf +/+ Or heterozygotes gsdf +/- ) The fertility of the fertilized eggs and the proportion of surviving embryos obtained by hybridization are significantly lower. The fertility and fertilized egg survival rate of Sissy sperm decreased to 25.58% -45.3% by 100% of fertilized eggs produced by normal group XX females and XY males of intact gsdf were not identical to those of the previously reported gsdf, which resulted in reduced fertility and embryo dysplasia, and the result of decreased survival rate was consistent [5]]。
TABLE 4 fertilization rates of Sissy medaka Male and Normal XY Male vs embryo survival rates
The absence of 3gsdf signal affects the estradiol/testosterone (E2/T) hormone level in blood and the ratio of the two
Real-time quantitative RT-PCR detection shows that 17-hydroxylase (cyp 17a 1) necessary for gonadal estrogen and androgen synthesis is highly expressed in male testis and positively correlated with testis development; while the expression level of the ovarian aromatase cyp19a, a key rate-limiting enzyme for estrogen synthesis, is closely related to female egg cell development (A in FIG. 11).
The loss of gsdf directly disrupts the differentiation and development of granulosa cells surrounding the egg cells, reducing the number of granulosa cells, thinning the granulosa cell layer, leading to a decrease in the expression of cyp19a produced by granulosa cells, leading to a barrier in oocyte development [5]. The expression of cyp19a was significantly lower than female levels, approaching male, in both the testis and the Sissy sperm ovaries of the transgene Tg cryGsdf2A-EGFP XX (FIG. 11A). It has been reported that the deletion of cyp19a, while not directly affecting early egg cell production, is essential for maintaining egg cell development and maturation [6]. Post-maleation of XX gonads after Cyp19a knockout occurs, producing XX testis, indicating that a decrease or deletion of Cyp19a eventually leads to maleation of germ cells and somatic cells [6].
The levels of E2 and T in serum were determined using an enzyme immunoassay kit and the results are summarized in FIG. 11B as described previously. Serum E2 and T levels were close to those of normal XY males (B in FIG. 11) in comparison to normal females and males, tg cryGsdf2A-EGFP XX males, consistent with the male phenotype of the second sex. Sissy individuals E2 and T are between normal females and males, and also conform to the male-female phenotype of the second sex characteristic hip fin, while the dorsal fin is female. The E2 to T ratio in normal female blood is almost 100 times that in normal male (B in FIG. 11), while the E2/T ratio in gsdf knocked-out females or Sissy is between normal male and female. In particular, the T levels of either XY or XX females with a loss of Gsdf were not significantly different from normal XX females, whereas XX males produced by overexpression of the Gsdf transgene, and blood T levels of the Sissy hermaphrodites were significantly higher than females, reflecting that the Gsdf signal could directly or indirectly raise testosterone levels (B in FIG. 11) consistent with male external characteristics (hip fin shape) (FIGS. 6-8).
qPCR also aligned amh/amhrII and fsh/lh receptor expression profiles from the normal and gsdf deleted groups. The transgenic gsdf signal was found to promote expression of cyp19b in the gonads (a in fig. 12). The levels of amh and amhrII expression were higher in the normal testis than in the ovary, were inhibited in the Gsdf knockout ovary, but were high in the Tg: cryGsdf2A-EGFP testis, indicating that amh and amhrII expression were also regulated and affected by the Gsdf signal (FIG. 12A). The Gsdf signal also inhibited the expression of follicle stimulating hormone receptor (fshr) and luteinizing hormone receptor (lhr) in the gonads (B in fig. 12). We found that lhr increased significantly in both Sissy and Tg: cryGsdf2A-EGFP XX males, whereas fshr decreased significantly in Gsdf-deleted ovaries, and increased significantly in Sissy, indicating that fshr expressing cells responded more strongly to Gsdf signals relative to lhr expressing cells (B in fig. 12).
Reference is made to:
1.Zhang,X.,et al.,Autosomal gsdfacts as a male sex initiator in thefish medaka.Scientific Reports,2016.6.19738.
2.Matsuda,M.,et al.,DMYis a Y-specific DM-domain gene requiredfor male development in the medakafish.Nature,2002.417(6888):p.559-63.
3.Magabo,K.S.,et al.,Expression ofbetaB(2)-crystallin mRNA andprotein in retina,brain,and testis.Invest OphthalmolVis Sci,2000.41(10):p.3056-60.
4.Vopalensky,P.,et al.,A lens-specific co-injection marker for medaka transgenesis.Biotechniques,2010.48(3):p.235-6.
5.Guan,G.,Sun K.,Zhang X.,Zhao X.,Li M.,Yan Y.,Wang Y.,Chen J.,Yi M.,and Hong Y.,Developmental tracing of oocyte development in gonadal soma-derived factor deficiency medaka(Oryzias latipes)using a transgenic approach.Mechanisms ofDevelopment 2017.143:p.53-61.
6.Nakamoto,M.,et al.,Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration andpartialfemale-to-male sex reversal afterpuberty.Mol Cell Endocrinol,2018.460:p.104-122.
the foregoing is merely a preferred embodiment of the present invention, and it should be noted that modifications and additions may be made to those skilled in the art without departing from the method of the present invention, which modifications and additions are also to be considered as within the scope of the present invention.
SEQUENCE LISTING
<110> Shanghai university of ocean
<120> method for establishing a model of a Sissy medaka simulating human spermatic ovarian syndrome
<130> /
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 30
<212> DNA
<213> artificial sequence
<400> 1
cttcccatcg attcgatgtc tttggcactc 30
<210> 2
<211> 30
<212> DNA
<213> artificial sequence
<400> 2
gcccttgctc accatgggcc cagggttttc 30
<210> 3
<211> 4971
<212> DNA
<213> artificial sequence
<400> 3
caggaaacag ctatgaccat gattacgcca agcgcgtagg gataacaggg taatgcgcgc 60
aattaaccct cactaaaggg aacaaaagct ggagctccac cgcggtggcg gccgctctag 120
aactagtccg aagcttgcaa tgcctgcagg tcgactctag aggatgggct cgacggccca 180
agctacatca agtgaccttt ttaaccaggt cagtgatttg tcatccattc gaaagctctg 240
gagagtctaa gataaaacat acaataaccc acacctcccc catagtcatt atatagaaaa 300
gagaggggaa aaaaagtgcc ctgtcccact gcgggcccct tttgtgctgt tcctgccaac 360
acagcagacc tcctgctata tagaccctgc tcccagcccc acacactcaa cagcaccatc 420
ccatccgacc tgccaacacc agccaagctt cccatcgatt cgatgtcttt ggcactcatt 480
gtcttgttaa tgcttcttgg ctcttcaatg gttattgcct ttgtcctgca tccgtcaagg 540
gaagagcctg cagcctctcc tgcatctact gtttcccacc acaggtgtca ggatgagtca 600
ttgcagtcct tcaggaagag tctccttgaa gctctcagcc tgcagacgga gccacgcctg 660
ccagctggcg ggctggacac tattcgagag cagtggcaga gaaccttcaa tgccgccatg 720
ggtgtcacgg acactacagc tccagtgctc tccagctcct ctgtgtcatg cgacagtgaa 780
aatgatacca gcctgaagtg ctgctccatg gccaccgagg tcttcatgaa agatctgggc 840
tgggacaatt gggtgatcta tcctctgagc ctgatcattg accggtgtgc tctctgcaat 900
tcctcggatc aaatagcgca gtgtccggca gcccatgatg gagtccagat cagaggctca 960
caggaccagg cgagctgctg caagcccacc tcccttgaaa tagtacccat cgtcttcatg 1020
gatgaaacca gcaccattgt catctcctcg gtgcagctag ctcgcggctg cggctgtgga 1080
ccaggcagcg cccagcagcc ctgcaaaaag gggtcaggtg ccacaaattt ctccctttta 1140
aaacaagcag gagatgttga agaaaaccct gggcccatgg tgagcaaggg cgaggagctg 1200
ttcaccgggg tggtgcccat cctggtcgag ctggacggcg acgtaaacgg ccacaagttc 1260
agcgtgtccg gcgagggcga gggcgatgcc acctacggca agctgaccct gaagttcatc 1320
tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg tgaccacctt cacctacggc 1380
gtgcagtgct tcagccgcta ccccgaccac atgaagcagc acgacttctt caagtccgcc 1440
atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg caactacaag 1500
acccgcgccg aggtgaagtt cgagggcgac accctggtga accgcatcga gctgaagggc 1560
atcgacttca aggaggacgg caacatcctg gggcacaagc tggagtacaa ctacaacagc 1620
cacaacgtct atatcatggc cgacaagcag aagaacggca tcaaggtgaa cttcaagatc 1680
cgccacaaca tcgaggacgg cagcgtgcag ctcgccgacc actaccagca gaacaccccc 1740
atcggcgacg gccccgtgct gctgcccgac aaccactacc tgagcaccca gtccgccctg 1800
agcaaagacc ccaacgagaa gcgcgatcac atggtcctgc tggagttcgt gaccgccgcc 1860
gggatcactc tcggcatgga cgagctgtac aagtaaagcg gccgcgactc tagaactata 1920
gtgagtcgta ttacgtagat ccagacatga taagatacat tgatgagttt ggacaaacca 1980
caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct attgctttat 2040
ttgtaaccat tataagctgc aataaacaag ttaacaacaa caattgcatt cattttatgt 2100
ttcaggttca gggggaggtg tgatatcaag cttatcgata ccgtcgacct cgaggggggg 2160
cccggtaccc aattcgccct atagtgagtc gtattacgcg cgcattaccc tgttatccct 2220
atcactggcc gtcgttttac aacgtcgtga ctgggaaaac cctggcgtta cccaacttaa 2280
tcgccttgca gcacatcccc ctttcgccag ctggcgtaat agcgaagagg cccgcaccga 2340
tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg gacgcgccct gtagcggcgc 2400
attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc gctacacttg ccagcgccct 2460
agcgcccgct cctttcgctt tcttcccttc ctttctcgcc acgttcgccg gctttccccg 2520
tcaagctcta aatcgggggc tccctttagg gttccgattt agtgctttac ggcacctcga 2580
ccccaaaaaa cttgattagg gtgatggttc acgtagtggg ccatcgccct gatagacggt 2640
ttttcgccct ttgacgttgg agtccacgtt ctttaatagt ggactcttgt tccaaactgg 2700
aacaacactc aaccctatct cggtctattc ttttgattta taagggattt tgccgatttc 2760
ggcctattgg ttaaaaaatg agctgattta acaaaaattt aacgcgaatt ttaacaaaat 2820
attaacgctt acaatttagt ggcacttttc ggggaaatgt gcgcggaacc cctatttgtt 2880
tatttttcta aatacattca aatatgtatc cgctcatgag acaataaccc tgataaatgc 2940
ttcaataata ttgaaaaagg aagagtatga gtattcaaca tttccgtgtc gcccttattc 3000
ccttttttgc ggcattttgc cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa 3060
aagatgctga agatcagttg ggtgcacgag tgggttacat cgaactggat ctcaacagcg 3120
gtaagatcct tgagagtttt cgccccgaag aacgttttcc aatgatgagc acttttaaag 3180
ttctgctatg tggcgcggta ttatcccgta ttgacgccgg gcaagagcaa ctcggtcgcc 3240
gcatacacta ttctcagaat gacttggttg agtactcacc agtcacagaa aagcatctta 3300
cggatggcat gacagtaaga gaattatgca gtgctgccat aaccatgagt gataacactg 3360
cggccaactt acttctgaca acgatcggag gaccgaagga gctaaccgct tttttgcaca 3420
acatggggga tcatgtaact cgccttgatc gttgggaacc ggagctgaat gaagccatac 3480
caaacgacga gcgtgacacc acgatgcctg tagcaatggc aacaacgttg cgcaaactat 3540
taactggcga actacttact ctagcttccc ggcaacaatt aatagactgg atggaggcgg 3600
ataaagttgc aggaccactt ctgcgctcgg cccttccggc tggctggttt attgctgata 3660
aatctggagc cggtgagcgt gggtctcgcg gtatcattgc agcactgggg ccagatggta 3720
agccctcccg tatcgtagtt atctacacga cggggagtca ggcaactatg gatgaacgaa 3780
atagacagat cgctgagata ggtgcctcac tgattaagca ttggtaactg tcagaccaag 3840
tttactcata tatactttag attgatttaa aacttcattt ttaatttaaa aggatctagg 3900
tgaagatcct ttttgataat ctcatgacca aaatccctta acgtgagttt tcgttccact 3960
gagcgtcaga ccccgtagaa aagatcaaag gatcttcttg agatcctttt tttctgcgcg 4020
taatctgctg cttgcaaaca aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc 4080
aagagctacc aactcttttt ccgaaggtaa ctggcttcag cagagcgcag ataccaaata 4140
ctgtccttct agtgtagccg tagttaggcc accacttcaa gaactctgta gcaccgccta 4200
catacctcgc tctgctaatc ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc 4260
ttaccgggtt ggactcaaga cgatagttac cggataaggc gcagcggtcg ggctgaacgg 4320
ggggttcgtg cacacagccc agcttggagc gaacgaccta caccgaactg agatacctac 4380
agcgtgagct atgagaaagc gccacgcttc ccgaagggag aaaggcggac aggtatccgg 4440
taagcggcag ggtcggaaca ggagagcgca cgagggagct tccaggggga aacgcctggt 4500
atctttatag tcctgtcggg tttcgccacc tctgacttga gcgtcgattt ttgtgatgct 4560
cgtcaggggg gcggagccta tggaaaaacg ccagcaacgc ggccttttta cggttcctgg 4620
ccttttgctg gccttttgct cacatgttct ttcctgcgtt atcccctgat tctgtggata 4680
accgtattac cgcctttgag tgagctgata ccgctcgccg cagccgaacg accgagcgca 4740
gcgagtcagt gagcgaggaa gcggaagagc gcccaatacg caaaccgcct ctccccgcgc 4800
gttggccgat tcattaatgc agctggcacg acaggtttcc cgactggaaa gcgggcagtg 4860
agcgcaacgc aattaatgtg agttagctca ctcattaggc accccaggct ttacacttta 4920
tgcttccggc tcgtatgttg tgtggaattg tgagcggata acaatttcac a 4971
<210> 4
<211> 24
<212> DNA
<213> artificial sequence
<400> 4
ccgggtgccc aagtgctccc gctg 24
<210> 5
<211> 24
<212> DNA
<213> artificial sequence
<400> 5
gatcgtccct ccacagagaa gaga 24
Claims (2)
1. A method for building a Sissy medaka model for simulating human sperm-ovarian syndrome, comprising the following steps:
a) Breeding of a homozygous female fish with a gsdfKO female medaka (XYgsdf) by using a gsdf-specific primer -/- ♀);
b) Tg crigsdf 2A-EGFP transgenic XX male fish (XXgsdf) was sorted using lens green fluorescence +/+ And (3) the following steps: constructing and linearizing a p817-gsdf2A-EGFP expression plasmid, and microinjecting fertilized eggs to obtain a stable inherited Tg cryGsdf2A-EGFP transgenic line, wherein the sequence of the p817-gsdf2A-EGFP expression plasmid is shown as SEQ ID NO. 3, and the fertilized eggs are fertilized eggs in 1 cell stage;
c) Genetic hybridization protocol: XX Male fish (XXgsdf) transgenic for cryGsdf2A-EGFP by Tg +/+ Female) and gsdfKO female (XYgsdf) -/- (ii) crossing to obtain a gsdf heterozygous XXTg male medaka (XXgsdf) +/- Female) and then with gsdfKO (XYgsdf) -/- (ii) the final obtaining of gsdfKO transgenic medaka, sissyA medaka model.
2. The method of claim 1, wherein the gsdfKO female medaka is obtained by knockout of endogenous gsdf with a zinc finger nuclease specific target.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811346983.9A CN111172189B (en) | 2018-11-13 | 2018-11-13 | Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811346983.9A CN111172189B (en) | 2018-11-13 | 2018-11-13 | Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111172189A CN111172189A (en) | 2020-05-19 |
CN111172189B true CN111172189B (en) | 2023-06-13 |
Family
ID=70651799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811346983.9A Active CN111172189B (en) | 2018-11-13 | 2018-11-13 | Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111172189B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936596A (en) * | 2012-08-23 | 2013-02-20 | 北京大学 | Medaka ovary structural protein gene promoter and applications thereof |
CN103724415A (en) * | 2013-12-31 | 2014-04-16 | 中山大学 | Epinephelus coioides sex control gene Rspo1 and preparation method and application thereof |
CN104745628A (en) * | 2015-04-16 | 2015-07-01 | 浙江万里学院 | Method for sex induction of hermaphrodite shrimps |
JP2015126729A (en) * | 2013-11-29 | 2015-07-09 | 大学共同利用機関法人自然科学研究機構 | Sex determination method for germ cell of fish, sex discrimination method, evaluation method for disturbance action of sex differentiation of test substance, hermaphrodite making method, early mature individual making method, germ cell, fish individual, gamete, and cultured cell |
WO2016153019A1 (en) * | 2015-03-26 | 2016-09-29 | 国立大学法人東京海洋大学 | Transplant fish production method, transplant fish, hybrid fish species production method, and hybrid fish species |
CN107937394A (en) * | 2017-12-04 | 2018-04-20 | 四川省农业科学院水产研究所 | A kind of acipenser dabryanus sexual gland difference expression gene GSDF and its screening technique |
-
2018
- 2018-11-13 CN CN201811346983.9A patent/CN111172189B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936596A (en) * | 2012-08-23 | 2013-02-20 | 北京大学 | Medaka ovary structural protein gene promoter and applications thereof |
JP2015126729A (en) * | 2013-11-29 | 2015-07-09 | 大学共同利用機関法人自然科学研究機構 | Sex determination method for germ cell of fish, sex discrimination method, evaluation method for disturbance action of sex differentiation of test substance, hermaphrodite making method, early mature individual making method, germ cell, fish individual, gamete, and cultured cell |
CN103724415A (en) * | 2013-12-31 | 2014-04-16 | 中山大学 | Epinephelus coioides sex control gene Rspo1 and preparation method and application thereof |
WO2016153019A1 (en) * | 2015-03-26 | 2016-09-29 | 国立大学法人東京海洋大学 | Transplant fish production method, transplant fish, hybrid fish species production method, and hybrid fish species |
CN104745628A (en) * | 2015-04-16 | 2015-07-01 | 浙江万里学院 | Method for sex induction of hermaphrodite shrimps |
CN107937394A (en) * | 2017-12-04 | 2018-04-20 | 四川省农业科学院水产研究所 | A kind of acipenser dabryanus sexual gland difference expression gene GSDF and its screening technique |
Non-Patent Citations (5)
Title |
---|
Developmental tracing of oocyte development in gonadal soma-derived factor deficiency medaka (Oryzias latipes) using a transgenic approach;GuijunGuan等;《Mechanisms of Development》;第143卷;第53-61页 * |
gsdf Is a Downstream Gene of dmrt1 That Functions in the Male Sex Determination Pathway of the Nile Tilapia;Jiang, Dong-Neng等;《Molecular Reproduction&Development》;第83卷(第6期);第497-508页 * |
Gsdf和Wt1在罗非鱼性别分化和性腺发育中的功能研究;江东能;《中国博士学位论文全文数据库 农业科技辑》(第2017年第01期);第D052-3页 * |
gsdf在青鳉鱼性腺发育过程中的功能研究;郭安宁等;《2016 年中国水产学会学术年会论文摘要集》;第1页 * |
用模式生物青概观硬骨鱼性别决定及性分化研究进展;亢逸等;《遗传》;第39卷(第06期);第441-454页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111172189A (en) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Løvoll et al. | Maternal transfer of complement components C3-1, C3-3, C3-4, C4, C5, C7, Bf, and Df to offspring in rainbow trout (Oncorhynchus mykiss) | |
Wang et al. | Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice | |
Weaver et al. | Novel zinc-responsive post-transcriptional mechanisms reciprocally regulate expression of the mouse Slc39a4 and Slc39a5 zinc transporters (Zip4 and Zip5) | |
Manuylov et al. | Conditional ablation of Gata4 and Fog2 genes in mice reveals their distinct roles in mammalian sexual differentiation | |
Tong et al. | Zebrafish monosex population reveals female dominance in sex determination and earliest events of gonad differentiation | |
Elizondo et al. | trpm7 regulation of in vivo cation homeostasis and kidney function involves stanniocalcin 1 and fgf23 | |
Hall et al. | Transforming growth factor-β3 (TGF-β3) knock-in ameliorates inflammation due to TGF-β1 deficiency while promoting glucose tolerance | |
JP2021533754A (en) | How to generate infertility and solitary offspring | |
Zhao et al. | Genetic analysis of activin/inhibin β subunits in zebrafish development and reproduction | |
CN111172189B (en) | Establishment method of Sissy medaka model for simulating human sperm ovarian syndrome | |
Wu et al. | Generation of fast growth Nile tilapia (Oreochromis niloticus) by myostatin gene mutation | |
Xiaohuan et al. | Characterization of the POU5F1 homologue in Nile tilapia: from expression pattern to biological activity | |
WO2008001778A1 (en) | Genetically modified animal and use thereof | |
Miao et al. | Loss of Fam20c causes defects in the acinar and duct structure of salivary glands in mice | |
Xiao et al. | Cortisol safeguards oogenesis by promoting follicular cell survival | |
US20190046618A1 (en) | Methods of inhibiting gonad maturation | |
JP2020536580A5 (en) | ||
Liang et al. | Figla gene roles in the proliferation of oocytes in the olive flounder Paralichthys olivaceus | |
US20120278911A1 (en) | Transgenic animal overexpressing luciferase and preparation method thereof | |
Liu et al. | Expression pattern and functional analysis of R-spondin1 in tongue sole Cynoglossus semilaevis | |
AU2017348348A1 (en) | Genetically modified mouse model for human hepatocyte xenotransplantation | |
Kang et al. | Molecular and biological aspects of early germ cell development in interspecies hybrids between chickens and pheasants | |
Emori et al. | PABPN1L is required for maternal mRNA degradation after meiosis resumption | |
Moran et al. | Optimising commercial traits through gene editing in aquaculture: Strategies for accelerating genetic improvement | |
Jia et al. | Analysis of imprinted messenger RNA expression in deceased transgenic cloned goats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |